The role of antibody-drug conjugates in the treatment of lung cancer
Abstract
Over the las0t decades, lung cancer treatment has improved immensely, mainly due to the incorporation of new targeted treatments and immunotherapy. A relatively new and potentially highly effective class of drugs, antibody-drug conjugates (ADCs), has been introduced to the clinical setting and is currently under intense investigation, alone and in combination with other molecules. This study aims to summarize the latest data on ADCs for lung cancer treatment and to analyze their potential, toxicity profile, and challenges.
Fields of Study & Subjects
HER2/EGFR in Cancer Research
Lung Cancer Treatments and Mutations
Advanced Breast Cancer Therapies
Publication details
- Journal / source
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Volume
- 16
- Pages
- 1757564–1757564
- Publication date
- 5 February 2026
- Language
- EN